Bioscience

A potential sale is on the table as BioXcel seeks a path forward.

Azitra said it is expanding into the consumer skin-care market as it continues development of its clinical pipeline.

Arvinas turns its first FDA drug approval into a potentially lucrative licensing deal.

New Haven-based Veradermics Inc. said Tuesday it has raised $766.8 million this year, giving the biotech company enough cash to fund its operations into 2030 as it advances a late-stage experimental hair-loss treatment.

A long-in-development breast cancer drug gives Arvinas its first commercial foothold.

Bristol-based IDEX Health & Science LLC, which makes components and systems for life sciences industries, has informed the city and state that it plans to shutter its operations this fall.

A Yale spinout called Wavelet is using AI to monitor fetal brain activity in real time — a potential breakthrough in a field that has relied on the same imperfect technology since the 1960s.

New Haven-based Rallybio Corp. said Monday its planned merger with a San Diego biotechnology company has been terminated.

Purdue Pharma has been dissolved following the conclusion of its bankruptcy case, putting into effect a $7.4 billion opioid settlement.

Four years in, Yale's startup engine has spun out 51 companies and helped attract more than $600 million — and its managing director says the pipeline of ideas shows no signs of slowing.